Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis

被引:5
|
作者
Nakai, Hajime [1 ,2 ]
Sato, Takumi [1 ]
Uno, Takashi [1 ]
Furukawa, Emiko [1 ]
Kawamura, Masato [1 ]
Takahashi, Hiroshi [3 ]
Watanabe, Akira [4 ]
Fujimura, Shigeru [1 ,4 ]
机构
[1] Tohoku Med & Pharmaceut Univ, Div Clin Infect Dis & Chemotherapy, Sendai, Miyagi, Japan
[2] Tohoku Rosai Hosp, Dept Pharm, Sendai, Miyagi, Japan
[3] Saka Gen Hosp, Dept Resp Med, Sendai, Miyagi, Japan
[4] Tohoku Univ, Inst Dev Aging & Canc, Res Div Dev Antiinfect Agents, Sendai, Miyagi, Japan
关键词
Mutant selection window; Streptococcus pneumoniae; Moraxella catarrhalis; Haemophilus influenzae; Quinolone resistance-determining region; URINARY-TRACT-INFECTIONS; IN-VITRO MODEL; RESISTANT MUTANTS; LEVOFLOXACIN; CIPROFLOXACIN; PHARMACOKINETICS; SUSCEPTIBILITY; SURVEILLANCE; TOSUFLOXACIN; HEALTHY;
D O I
10.1016/j.jiac.2017.08.009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Community-acquired pneumonia and otitis media are caused by several bacterial species, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. For the treatment of these diseases, various quinolones are frequently used. We determined the mutant prevention concentration (MPC) of four quinolones, levofloxacin, sitafloxacin, tosufloxacin, and garenoxacin, using 92 clinical isolates and evaluated each mutant selection window (MSW). Furthermore, the DNA sequence of the quinolone resistance-determining region (QRDR) for the resistant mutant selected based on the MSW was determined. The MIC90 and MPC90 of levofloxacin were 0.781 mu g/mL and 6.250 mu g/mL for S. pneumoniae and 0.049 mu g/mL and 1.563 mu g/mL for M. catarrhalis and were higher than those for the other three quinolones. In addition, 5 strains of 30 S. pneumoniae (16.7%) selected based on the MSW of levofloxacin acquired resistance to only levofloxacin. In these 5 strains, a mutation of gyrA and/or parC was detected. In this study, no resistant mutant was selected in the MSW of any of the other three quinolones. On the other hand, clinical isolates of H. influenzae showed no resistance by all quinolone exposure. Finally, The MIC value and the mutation status in the QRDR did not change after 14 passages in antibiotic-free medium. In conclusion, our findings suggest that the increased use of levofloxacin may contribute to the increased quinolone-resistance of S. pneumoniae and M. catarrhalis. (c) 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
  • [1] Mutant prevention concentration of four quinolones against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Nakai, Hajime
    Sato, Takumi
    Uno, Takashi
    Furukawa, Emiko
    Kawamura, Masato
    Takahashi, Hiroshi
    Watanabe, Akira
    Fujimura, Shigeru
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S82 - S82
  • [2] In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Flamm, Robert K.
    Rhomberg, Paul R.
    Huband, Michael D.
    Farrell, David J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (10) : 6381 - 6385
  • [3] Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis
    Blondeau, JM
    Suter, M
    Borsos, S
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 : 25 - 30
  • [4] Activities of faropenem, an oral β-lactam, against recent US isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Critchley, IA
    Karlowsky, JA
    Draghi, DC
    Jones, ME
    Thornsberry, C
    Murfitt, K
    Sahm, DF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) : 550 - 555
  • [5] Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents
    Blondeau, JM
    Vaughan, D
    Laskowski, R
    Borsos, S
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 17 (06) : 457 - 464
  • [6] In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Brueggemann, AB
    Doern, GV
    Huynh, HK
    Wingert, EM
    Rhomberg, PR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) : 447 - 449
  • [7] The Activity of Fluoroquinolones and Other Antimicrobial Agents Against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Clyde Thornsberry
    P. Ogilvie
    H. P. Holley
    M. L. Hickey
    M. E. Jones
    I. A. Critchley
    D. F. Sahm
    [J]. Drugs, 1999, 58 : 346 - 348
  • [8] The activity of fluoroquinolones and other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Thornsberry, C
    Ogilvie, P
    Holley, HP
    Hickey, ML
    Jones, ME
    Critchley, IA
    Sahm, DF
    [J]. DRUGS, 1999, 58 (Suppl 2) : 346 - 348
  • [9] Oral antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates from Japanese children
    Nishi, J
    Yoshinaga, M
    Tokuda, K
    Masuda, K
    Masuda, R
    Kamenosono, A
    Manago, K
    Miyata, K
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (02) : 130 - 135
  • [10] Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics
    Hsueh, PR
    Huang, WK
    Shyr, JM
    Lau, YJ
    Liu, YC
    Luh, KT
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2004, 103 (09) : 664 - 670